CAMBRIDGE, Mass.--Develop mental biology-based biotech Ontogeny and Genzyme Molecu lar Oncology, developer of gene-based approaches to cancer diagnosis and therapy, announced a collaborative agreement under which Genzyme will produce its proprietary Sage libraries to enable Ontogeny to analyze differential gene expression. Sage is a high-efficiency, high-throughput method of simultaneously detecting and measuring the expression levels of virtually all genes expressed in a cell at a given time.
Using RNA supplied by Ontogeny, Genzyme will produce RNA Sage libraries that Ontogeny will incorporate into its developmental biology discovery system. Identified genes will be processed through Ontogeny's screening system to validate leads and targets. Financial terms were not disclosed.
In another deal, Genzyme agreed to provide genetic research firm Hexagen of Cambridge, UK, with Sage technology for use in Hexagen's disease discovery programs. Hexagen will pay Genzyme an undisclosed service fee and will retain exclusive rights to information that results from the collaboration.